Présentations du GINECO à l'ASCO 2022

Par le biais de cette page, vous pouvez accéder à l'ensemble des présentations du GINECO à l'ASCO (American Society of Clinical Oncology).


Le GINECO à l'ASCO 2022


Page d'accès aux présentations du GINECO au congrès de l'ASCO qui s'est tenu du 3 au 7 juin 2022

Comme les années précédentes le GINECO était, cette année encore, très présent à l'ASCO avec :


1 poster discussion :

  • DESKTOP III – sub-analyse : Role of cytoreductive surgery for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial. Plusieurs posters


Plusieurs posters :

  • KELIM GOG0218 : Identification of the ovarian cancer patients experiencing the highest benefit from bevacizumab in first line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG 0218 validation study


  • CHIVA RT : Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.


  • INEOV (Pathological response rate) : Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates.


  • OREO (Analyse exploratoire) : Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.


  • PAOLA-1 (Qol) : Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).


  • PAOLA-1 (Twist) : Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.


  • PAOLA-1 (BRCA sub types) : Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.


  • TEDOVA : TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with Pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Haut de page
Modifié le 26-06-2019 17:22:26